Chemistry42
Insilico Medicine
Commercial generative chemistry platform using an ensemble of deep learning architectures. Part of the Pharma.AI platform. Has molecules in Phase I/II clinical trials.
Best For
Full AI-driven drug design from target to IND (has clinical candidates)
License
Commercial
Strengths
- +Clinical-stage molecules
- +Ensemble architecture
- +Integrated with PandaOmics
Limitations
- −Fully proprietary
- −Expensive commercial licensing
R&D Pipeline Coverage
Related Tools
More in Generative Design
RFdiffusion
Baker Lab / IPD (University of Washington)
Diffusion-based generative model for de novo protein backbone design. Generates novel protein structures conditioned on binding targets, symmetry, or functional sites.
RFdiffusion2
Baker Lab / IPD (University of Washington)
Successor to RFdiffusion using flow matching. Designs enzymes directly from active site geometry (theozyme) specifications.
ProteinMPNN
Baker Lab / IPD (University of Washington)
Inverse folding model: generates amino acid sequences predicted to fold into a target 3D backbone structure. Standard component of all modern protein design pipelines.
Stay updated on Chemistry42
Weekly newsletter covering AI tool releases, benchmarks, and what practitioners actually use.